RxDoctor Payments Data

Danielle Stone, MD

Cardiovascular Disease · Harlingen, TXNPI 1710371612

Payments from drug & device makers

$5,765in general payments, 2019–2025

Across 78 payments — averaging $73.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Abbott$853
  • E.r. Squibb & Sons, L.L.C.$294
  • Shockwave Medical, Inc$293
  • AstraZeneca$240
  • Astellas Pharma US Inc$198
  • plus $1K from 13 others

What the payments were for

  • Travel & lodging$3,04353%
  • Food & beverage$2,42442%
  • Education$2985%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,765 in reported general payments places this provider in the 60th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$154,214
Medicare patients
678
Services billed
1,885

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban178$198,112
EntrestoSacubitril/Valsartan29$34,993
XareltoRivaroxaban21$20,822
VascepaIcosapent Ethyl11$3,604
Metoprolol Succinate222$2,697
Nifedipine ErNifedipine53$1,959
Ranolazine ErRanolazine15$1,835
Losartan Potassium202$1,806
Cilostazol68$1,769
Atorvastatin Calcium199$1,667
Rosuvastatin Calcium139$1,616
Pindolol19$1,501
Lisinopril234$1,395
Hydralazine Hcl121$1,105
ClopidogrelClopidogrel Bisulfate71$1,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$17$34,99329 claims
Johnson & JohnsonXarelto$15$20,82221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Harlingen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →